Adaptive Biotechnologies Corporation (ADPT) Financials
ADPT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 640.7 million | 490.0 million |
| March 31, 2026 | 505.9 million | 281.7 million |
| Dec. 31, 2025 | 512.7 million | 287.7 million |
| Sept. 30, 2025 | 490.6 million | 286.4 million |
ADPT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -7.6 million | 11.1 million |
| March 31, 2026 | -10.3 million | 11.9 million |
| Dec. 31, 2025 | 1.4 million | 12.7 million |
| Sept. 30, 2025 | -7.5 million | 13.3 million |
ADPT Net Income
No data available :(
ADPT Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 344.3 million | 334.9 million | 66.8 million |
| March 31, 2026 | 218.3 million | 124.7 million | 69.1 million |
| Dec. 31, 2025 | 227.0 million | 196.8 million | 70.2 million |
| Sept. 30, 2025 | 212.8 million | - | 81.8 million |
ADPT Shares Outstanding
ADPT Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 1.2 million | 19.2 million | 47.6 million | 26.4 million |
| March 31, 2026 | 796000 | 23.6 million | 47.3 million | 26.3 million |
| Dec. 31, 2025 | 636000 | 21.8 million | 44.0 million | 24.5 million |
| Sept. 30, 2025 | 409000 | 23.7 million | 41.4 million | 23.5 million |
ADPT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 71.6 million | 20.2 million |
| March 31, 2026 | 70.9 million | 18.7 million |
| Dec. 31, 2025 | 71.7 million | 18.2 million |
| Sept. 30, 2025 | 94.0 million | 18.2 million |
ADPT Revenue by Segment
Graph available only for paid members. Upgrade to see it.
ADPT
Price: $24.74
52 week price:
Earnings Per Share: -0.40 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.2 million
Market Capitalization: 3.7 billion